MiR-595 targeting regulation of SOX7 expression promoted cell proliferation of human glioblastoma - 02/05/16
, Jianxin Zhu b, Yilei Xiao bBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 5 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Increasing evidence indicated that dysregulation of microRNAs (miRNAs) were involved with human disease including cancer. Recently, miR-595 was reported as a tumor promoter in malignant mesothelioma. However, the underlying mechanism of miR-595 in human glioblastoma (GBM) cells have not been well elucidated. Therefore, in this study, we investigated the biological functions and molecular mechanisms of miR-595 in human GBM. MiR-595 expression was significantly upregulated in GBM tissues and cells. We modified miR-595 levels in GBM cells and investigated their effects on the cell proliferation by MTT, colony formation and anchorage-independent growth assays. We found that miR-595 significantly increased GBM cell proliferation. Bioinformatic analysis predicted that miR-595 may target the 3′-UTR of SOX7and suppressed its translation, and further confirmed by luciferase assay. In sum, these observations together indicated that miR-595 played a critical role in carcinogenesis by suppression of SOX7, and may serve as a therapeutic target for the treatment of GBM.
Le texte complet de cet article est disponible en PDF.Keywords : miR-595, Glioblastoma, SOX7, Cell proliferation
Plan
Vol 80
P. 121-126 - mai 2016 Retour au numéro
Article précédent
- ABCB1 variants confer susceptibility to primary open-angle glaucoma and predict individual differences to latanoprost treatment
- Hai Liu, Zhong-Kun Yang, Yan Li, Wen-Jia Zhang, Ying-Ting Wang, Xuan-Chu Duan
- Reinforcing B16F10/GPI-IL-21 vaccine efficacy against melanoma by injecting mice with shZEB1 plasmid or miR200c agomir
- Xiaoying Wang, Fengshu Zhao, Fangfang Shi, Xiangfeng He, Meng Pan, Di Wu, Miao Li, Yunxia Zhang, Jun Dou
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?